Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array
✍ Scribed by Steffen Backert; Marcos Gelos; Ursula Kobalz; Marie-Luise Hanski; Christian Böhm; Benno Mann; Nicole Lövin; Alexei Gratchev; Ulrich Mansmann; Mary Pat Moyer; Ernst-Otto Riecken; Christoph Hanski
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- French
- Weight
- 212 KB
- Volume
- 82
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Expression of selected genes coding for proteins with defined cellular functions was analysed in human cell lines derived from normal colonic mucosa, non-mucinous colonic carcinomas and mucinous colonic carcinomas. Altered expression of 10 genes in colon carcinoma cells was found by using a cDNA array; 6 of these alterations (60%) were confirmed by Northern blotting or semi-quantitative reverse transcriptionpolymerase chain reaction (RT-PCR). Among these 6 genes, 3 transcription factors as well as the topoisomerase II ␣ and the mitosis inhibitor WEE1Hu gene were significantly suppressed in the tumour cell lines. In addition, the gene coding for the cell cycle inhibitor p21 was overexpressed only in cell lines derived from mucinous carcinomas. The significant suppression of the kinase WEE1Hu gene in carcinoma cells of both phenotypes and the tendency of the mucinous phenotype to overexpress p21 protein were confirmed in human colon carcinoma tissues. Our data show that the cDNA array method permits a correct identification of changes in gene expression with a relatively high accuracy. The different expression of the p21 gene in the non-mucinous and mucinous carcinoma cells supports the hypothesis that these phenotypes may develop along different genetic pathways. The detection of WEE1Hu gene suppression in colon carcinoma cells and tissues suggests its potential role in tumourigenesis.
📜 SIMILAR VOLUMES
## Abstract ## Objective To compare the chondrogenic potential of human bone marrow–derived mesenchymal stem cells (BMSC) and adipose tissue–derived stromal cells (ATSC), because the availability of an unlimited cell source replacing human chondrocytes could be strongly beneficial for cell therapy